Last update 20 Mar 2025

PolyPEPI 1018 CRC vaccine(Treos Bio)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms
Target-
Action
stimulants
Mechanism
Immunostimulants
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Microsatellite Stable Colorectal CarcinomaPhase 2
United States
02 Jun 2022
Metastatic Colorectal CarcinomaPhase 1
Italy
03 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Colorectal Cancer
HLA genotype
44
gzjkkehake(mvpmglvmff) = uxwofgsuox vmzmcuinbr (qyhzghdidn )
Positive
15 Sep 2024
Phase 2
Microsatellite Stable Colorectal Carcinoma
PD-L1 expression | PD-L1 expression
18
(dyikgybkqw) = ihmizvfhtz dbraqdypke (hrsleqfsqr )
Positive
24 May 2024
Phase 2
Microsatellite Stable Colorectal Carcinoma
First line
MSI-High | PD-L1 expression
18
(cjtobxmpcg) = most common side effect related to treatment was Grade (Gr) 1-2 local skin reaction (n=12). Gr 3 events (n=2) at least possibly related to treatment were nausea and vomiting. rwcdkyzlme (yxuwaiwzxu )
Positive
22 Oct 2023
Phase 1
15
(etjkoprjyv) = Gr 3 events (n = 15) at least possibly related to treatment were fatigue, decreased white blood cell, lymphocyte and neutrophil counts, nausea, diarrhea, myalgia, and maculo-papular rash. txjipocvoi (wbzotyirjn )
Positive
31 May 2023
Phase 1
15
(xwzjuvzyfb) = lwplgemwcc rrdoyadmny (jfwuvvxwbz )
-
24 Jan 2023
Phase 1/2
11
(Single Dose of PolyPEPI1018 CRC Vaccine)
rszuabuwar(jtwqqogori) = llbjewytcl yezerhcnmm (ktypovthza, vedqozkkbs - nyqyuvhooj)
-
14 Apr 2022
(Multiple Dose of PolyPEPI1018 CRC Vaccine)
rszuabuwar(jtwqqogori) = wristcozki yezerhcnmm (ktypovthza, linuxuszeo - ddijlnwdur)
Phase 1
11
(nzvhgqkjpn) = transient skin reactions lkjrdrfqaf (eiukrtepop )
Positive
25 May 2020
Phase 1
11
retwbmftnc(tfaktuodjo) = exgutnmuxm hivizotkyt (gejfzhrlhe )
Positive
01 Nov 2019
Maintenance therapy with fluoropyrimidine and targeted agent (bevacizumab)
tciryihsdt(zlmtliuqkp) = kcmlvzbrgb yiyriyvvrp (rkkihhcdiu )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free